UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 337

Sortiert nach

Rezafungin and invasive candida infections: a new game changing antifungal?

The Lancet (British edition), 2023-01, Vol.401 (10370), p.3-5

Guinea, Jesús

2023

Volltextzugriff (PDF)

New trends in antifungal treatment: What is coming up?

Revista española de quimioterapia, 2023-11, Vol.36 Suppl 1 (Suppl1), p.59-63

Guinea, J

2023

Volltextzugriff (PDF)

Emerging multidrug-resistant Candida species

Current opinion in infectious diseases, 2017-12, Vol.30 (6), p.528-538

2017

Volltextzugriff (PDF)

EUCAST-Obtained Olorofim MICs against Aspergillus and Scedosporium Species and Lomentospora prolificans Showed High Agreements between Visual Inspection and Spectrophotometric Readings

Antimicrobial agents and chemotherapy, 2022-09, Vol.66 (9), p.e0084922-e0084922

2022

Volltextzugriff (PDF)

Production of biofilm by Candida and non- Candida spp. isolates causing fungemia: Comparison of biomass production and metabolic activity and development of cut-off points

International journal of medical microbiology, 2014-11, Vol.304 (8), p.1192-1198

2014

Volltextzugriff (PDF)

In vitro activity of olorofim against Aspergillus fumigatus sensu lato clinical isolates: activity is retained against isolates showing resistance to azoles and/or amphotericin B

Clinical microbiology and infection, 2022-09, Vol.28 (9), p.1291-1291.e10

2022

Volltextzugriff (PDF)

Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity

Mycoses, 2021-02, Vol.64 (2), p.132-143

2021

Volltextzugriff (PDF)

Monitoring the Epidemiology and Antifungal Resistance of Yeasts Causing Fungemia in a Tertiary Care Hospital in Madrid, Spain: Any Relevant Changes in the Last 13 Years?

Antimicrobial agents and chemotherapy, 2021-03, Vol.65 (4)

2021

Volltextzugriff (PDF)

Amphotericin B, itraconazole, posaconazole, and isavuconazole MICs against clinical Mucorales isolates obtained by visual inspection and spectrophotometric reading according to the EUCAST 9.4 procedure

Medical mycology (Oxford), 2023-04, Vol.61 (5)

2023

Volltextzugriff (PDF)

In vitro activity of ibrexafungerp against Candida species isolated from blood cultures. Determination of wild-type populations using the EUCAST method

Clinical microbiology and infection, 2022-01, Vol.28 (1), p.140.e1-140.e4

2022

Volltextzugriff (PDF)

Fungemia due to rare opportunistic yeasts: data from a population-based surveillance in Spain

Medical mycology (Oxford), 2017-02, Vol.55 (2), p.125-136

2017

Volltextzugriff (PDF)

Multicenter evaluation of the Panbio™ COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection

Clinical microbiology and infection, 2021-05, Vol.27 (5), p.758-761

2021

Volltextzugriff (PDF)

In vitro activity of ibrexafungerp and comparators against Candida albicans genotypes from vaginal samples and blood cultures

Clinical microbiology and infection, 2021-06, Vol.27 (6), p.915.e5-915.e8

2021

Volltextzugriff (PDF)

Reduction in Percentage of Clusters of Candida albicans and Candida parapsilosis Causing Candidemia in a General Hospital in Madrid, Spain

Journal of clinical microbiology, 2018-07, Vol.56 (7)

2018

Volltextzugriff (PDF)

Spectrophotometric azole and amphotericin B MIC readings against Aspergillus fumigatus sensu lato using the EUCAST 9.3.2 methodology. Are ≥90 and ≥95% fungal growth inhibition endpoints equally suitable?

Medical mycology (Oxford), 2021-12, Vol.60 (1)

2021

Volltextzugriff (PDF)

Invasive Scedosporium and Lomentosora infections in the era of antifungal prophylaxis: A 20‐year experience from a single centre in Spain

Mycoses, 2020-11, Vol.63 (11), p.1195-1202

2020

Volltextzugriff (PDF)

Yeasts from blood cultures in the wake of the COVID-19 pandemic in a tertiary care hospital: Shift in species epidemiology, steady low antifungal resistance and full in vitro ibrexafungerp activity

Medical mycology (Oxford), 2023-07, Vol.61 (7)

2023

Volltextzugriff (PDF)

Azole-Resistant Aspergillus fumigatus Clinical Isolate Screening in Azole-Containing Agar Plates (EUCAST E.Def 10.1): Low Impact of Plastic Trays Used and Poor Performance in Cryptic Species

Antimicrobial agents and chemotherapy, 2021-07, Vol.65 (8), p.e0048221-e0048221

2021

Volltextzugriff (PDF)

Gastrointestinal tract Candida spp colonization shows mostly a monoclonal pattern: an intra-patient pilot study

Medical mycology (Oxford), 2022-06, Vol.60 (6)

2022

Volltextzugriff (PDF)

The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp

Journal of antimicrobial chemotherapy, 2017-07, Vol.72 (7), p.1969-1976

2017

Volltextzugriff (PDF)

Comparison of the antifungal activity of micafungin and amphotericin B against Candida tropicalis biofilms

Journal of antimicrobial chemotherapy, 2016-09, Vol.71 (9), p.2498-2501

2016

Volltextzugriff (PDF)

Aspergillus citrinoterreus, a new species of section Terrei isolated from samples of patients with nonhematological predisposing conditions

Journal of clinical microbiology, 2015-02, Vol.53 (2), p.611-617

2015

Volltextzugriff (PDF)

Comparison of Two Highly Discriminatory Typing Methods to Analyze Aspergillus fumigatus Azole Resistance

Frontiers in microbiology, 2018-07, Vol.9, p.1626-1626

2018

Volltextzugriff (PDF)

Candida biomarkers in patients with candidaemia and bacteraemia

Journal of antimicrobial chemotherapy, 2015-08, Vol.70 (8), p.2354-2361

2015

Volltextzugriff (PDF)

1 – 25 von 337

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(313)
Mit Volltextzugriff
(322)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(240)
Life Sciences & Biomedicine
(225)
Microbiology
(143)
Humans
(133)
Infectious Diseases
(111)
Mycology
(72)
Pharmacology & Pharmacy
(62)
Antifungal Agents - Pharmacology
(61)
Male
(53)
Female
(51)
Biological And Medical Sciences
(46)
Microbial Sensitivity Tests
(43)
Middle Aged
(40)
Antifungal Agents - Therapeutic Use
(38)
Antifungal Agents
(37)
Aged
(36)
Candida
(34)
Adult
(33)
Candidemia
(31)
Drug Resistance, Fungal
(27)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Rezafungin and invasive candida infections: a new game changing antifungal?

New trends in antifungal treatment: What is coming up?

Emerging multidrug-resistant Candida species

EUCAST-Obtained Olorofim MICs against Aspergillus and Scedosporium Species and Lomentospora prolificans Showed High Agreements between Visual Inspection and Spectrophotometric Readings

Production of biofilm by Candida and non- Candida spp. isolates causing fungemia: Comparison of biomass production and metabolic activity and development of cut-off points

In vitro activity of olorofim against Aspergillus fumigatus sensu lato clinical isolates: activity is retained against isolates showing resistance to azoles and/or amphotericin B

Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity

Monitoring the Epidemiology and Antifungal Resistance of Yeasts Causing Fungemia in a Tertiary Care Hospital in Madrid, Spain: Any Relevant Changes in the Last 13 Years?

Amphotericin B, itraconazole, posaconazole, and isavuconazole MICs against clinical Mucorales isolates obtained by visual inspection and spectrophotometric reading according to the EUCAST 9.4 procedure

In vitro activity of ibrexafungerp against Candida species isolated from blood cultures. Determination of wild-type populations using the EUCAST method

Fungemia due to rare opportunistic yeasts: data from a population-based surveillance in Spain

Multicenter evaluation of the Panbio™ COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection

In vitro activity of ibrexafungerp and comparators against Candida albicans genotypes from vaginal samples and blood cultures

Reduction in Percentage of Clusters of Candida albicans and Candida parapsilosis Causing Candidemia in a General Hospital in Madrid, Spain

Spectrophotometric azole and amphotericin B MIC readings against Aspergillus fumigatus sensu lato using the EUCAST 9.3.2 methodology. Are ≥90 and ≥95% fungal growth inhibition endpoints equally suitable?

Invasive Scedosporium and Lomentosora infections in the era of antifungal prophylaxis: A 20‐year experience from a single centre in Spain

Yeasts from blood cultures in the wake of the COVID-19 pandemic in a tertiary care hospital: Shift in species epidemiology, steady low antifungal resistance and full in vitro ibrexafungerp activity

Azole-Resistant Aspergillus fumigatus Clinical Isolate Screening in Azole-Containing Agar Plates (EUCAST E.Def 10.1): Low Impact of Plastic Trays Used and Poor Performance in Cryptic Species

Gastrointestinal tract Candida spp colonization shows mostly a monoclonal pattern: an intra-patient pilot study

The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp

Comparison of the antifungal activity of micafungin and amphotericin B against Candida tropicalis biofilms

Aspergillus citrinoterreus, a new species of section Terrei isolated from samples of patients with nonhematological predisposing conditions

Comparison of Two Highly Discriminatory Typing Methods to Analyze Aspergillus fumigatus Azole Resistance

Breakthrough invasive fungal infection among patients with haematologic malignancies: A national, prospective, and multicentre study

Candida biomarkers in patients with candidaemia and bacteraemia

Suchergebnisse filtern